John T. Wei

TL;DR: A first prospective North American multicenter study to characterize TMPRSS2-ERG prostate cancer prevalence in a cohort of patients undergoing needle biopsy irrespective of whether or not they subsequently undergo prostatectomy shows that this gene rearrangement is common among North American men who have prostate cancer onBiopsy, is absent in benign prostate biopsy, and is associated with specific morphologic features.

TL;DR: A definition of these MID values is essential for the researcher or clinician to understand when changes in symptom burden among prostate cancer survivors are clinically relevant.

TL;DR: The new phi test outperforms its individual components of total, free and [-2]proPSA for the identification of clinically significant prostate cancer and may be useful as part of a multivariable approach to reduce prostate biopsies and over diagnosis.

TL;DR: In this paper, the authors conducted an unbiased analysis to identify RNA biomarkers associated with metastatic progression after prostatectomy and found that high SChLAP1 expression was significantly prognostic for metastatic disease progression of prostate cancer.

TL;DR: By differentiating the risk of low- vs high-grade disease on biopsy, the new PCPTRC 2.0 better enables physician-patient counseling concerning whether to proceed to biopsy.